BMJ | 2019

No-deal Brexit may worsen drug shortages, pharmacists warn

 
 
 

Abstract


The Royal Pharmaceutical Society has expressed concern about drug shortages in a no-deal Brexit despite the government’s “multi-layered approach” to mitigate risks.\n\nDocuments compiled this month by the Cabinet Office under the codename Operation Yellowhammer, which were leaked to the Sunday Times on 18 August, set out the likely effect of Britain leaving the European Union without a deal.12\n\nThey said that, because three quarters of medicines come to the UK through the main Channel crossing between the UK and France—where disruption is expected to last as long as six months after a no-deal Brexit—these medicines were particularly vulnerable to severe delays.\n\n“While some products can be stockpiled, others cannot because of short shelf lives. It will not be practical to stockpile six months’ supplies,” the documents said.\n\nThey added that the Department for Health and Social Care was developing …

Volume 366
Pages None
DOI 10.1136/bmj.l5226
Language English
Journal BMJ

Full Text